These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 23190693)

  • 1. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
    Dewas CV; Maingon P; Dalban C; Petitfils A; Peignaux K; Truc G; Martin E; Khoury C; Dewas S; Créhange G
    Radiat Oncol; 2012 Nov; 7():201. PubMed ID: 23190693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
    Agarwal MS; Hitchcock KE; Morris CG; George TJ; Mendenhall WM; Zlotecki RA
    Curr Oncol; 2019 Aug; 26(4):e515-e521. PubMed ID: 31548820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.
    Thind G; Johal B; Follwell M; Kennecke HF
    Radiat Oncol; 2014 May; 9():124. PubMed ID: 24885554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis.
    Koerber SA; Slynko A; Haefner MF; Krug D; Schoneweg C; Kessel K; Kopp-Schneider A; Herfarth K; Debus J; Sterzing F
    Radiat Oncol; 2014 May; 9():113. PubMed ID: 24886574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions.
    Yates A; Carroll S; Kneebone A; Tse R; Horvath L; Byrne C; Solomon M; Hruby G
    Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):700-7. PubMed ID: 26382849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
    Yeung R; McConnell Y; Warkentin H; Graham D; Warkentin B; Joseph K; Doll CM
    Radiat Oncol; 2015 Apr; 10():92. PubMed ID: 25903798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.
    Oliveira SC; Moniz CM; Riechelmann R; Alex AK; Braghirolli MI; Bariani G; Nahas C; Hoff PM
    J Gastrointest Cancer; 2016 Mar; 47(1):75-81. PubMed ID: 26691173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haematotoxicity in IMRT/VMAT curatively treated anal cancer.
    Lohynská R; Nýdlová A; Drbohlavová T; Mazaná E; Jirkovská M; Veselský T; Malinová B; Stankušová H
    Klin Onkol; 2020; 33(4):288-294. PubMed ID: 32894958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer.
    Boda-Heggemann J; Weiss C; Schneider V; Hofheinz RD; Haneder S; Michaely H; Wertz H; Ronellenfitsch U; Hochhaus A; Wenz F; Lohr F
    Strahlenther Onkol; 2013 May; 189(5):417-23. PubMed ID: 23558673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
    Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensity-modulated radiotherapy improves survival and reduces treatment time in squamous cell carcinoma of the anus: A National Cancer Data Base study.
    Elson JK; Kachnic LA; Kharofa JR
    Cancer; 2018 Nov; 124(22):4383-4392. PubMed ID: 30329160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects.
    Koerber SA; Seither B; Slynko A; Haefner MF; Krug D; Liermann J; Adeberg S; Herfarth K; Debus J; Sterzing F
    Tumori; 2019 Apr; 105(2):174-180. PubMed ID: 30484384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option.
    Meulendijks D; Dewit L; Tomasoa NB; van Tinteren H; Beijnen JH; Schellens JH; Cats A
    Br J Cancer; 2014 Oct; 111(9):1726-33. PubMed ID: 25167226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant chemoradiotherapy with Cisplatin plus 5-Fluorouracil for anal squamous cell carcinoma.
    El-Hadaad HA; Wahba HA; Roshdy S
    J Gastrointest Cancer; 2015 Jun; 46(2):156-60. PubMed ID: 25810165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
    Ng M; Ho H; Skelton J; Guerrieri M; Guiney M; Chao M; Blakey D; Macleod C; Amor H; Subramanian B; Melven L
    Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):634-641. PubMed ID: 30049649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer.
    Nilsson MP; Johnsson A; Scherman J
    Radiat Oncol; 2021 Aug; 16(1):152. PubMed ID: 34399812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity-modulated Radiation Therapy for Anal Cancer: Results From a Multi-Institutional Retrospective Cohort Study.
    Call JA; Prendergast BM; Jensen LG; Ord CB; Goodman KA; Jacob R; Mell LK; Thomas CR; Jabbour SK; Miller RC
    Am J Clin Oncol; 2016 Feb; 39(1):8-12. PubMed ID: 24401669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
    James RD; Glynne-Jones R; Meadows HM; Cunningham D; Myint AS; Saunders MP; Maughan T; McDonald A; Essapen S; Leslie M; Falk S; Wilson C; Gollins S; Begum R; Ledermann J; Kadalayil L; Sebag-Montefiore D
    Lancet Oncol; 2013 May; 14(6):516-24. PubMed ID: 23578724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
    Deenen MJ; Dewit L; Boot H; Beijnen JH; Schellens JH; Cats A
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e201-7. PubMed ID: 23517808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns and Predictors of Relapse Following Radical Chemoradiation Therapy Delivered Using Intensity Modulated Radiation Therapy With a Simultaneous Integrated Boost in Anal Squamous Cell Carcinoma.
    Shakir R; Adams R; Cooper R; Downing A; Geh I; Gilbert D; Jacobs C; Jones C; Lorimer C; Namelo WC; Sebag-Montefiore D; Shaw P; Muirhead R
    Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):329-339. PubMed ID: 31629837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.